This study investigates advanced pancreatic cancer. It will look at how well onvansertib works with NALIRIFOX for people with this condition.
The study will evaluate the safety and effectiveness of the investigational medication to see if it can improve treatment options for this type of cancer.
- Who can participate: Adults aged 18 and older with advanced pancreatic cancer who have not received previous treatment in the metastatic setting may participate. They must have a good performance status and measurable disease.
- Study details: Participants will take the investigational medication orally. Some participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.